Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-10-07 5:07 pm Purchase | 2024-09-30 | 13G | Cue Biopharma, Inc. CUE | Bleichroeder LP | 6,127,662 9.990% | 3,372,634 (+122.42%) | Filing History |
| 2024-03-11 6:40 pm Purchase | 2024-02-27 | 13G | Cue Biopharma, Inc. CUE | Bleichroeder LP | 2,755,028 6.110% | 2,755,028 (New Position) | Filing History |
| 2024-02-07 5:09 pm Sale | 2024-01-31 | 13G | Cue Biopharma, Inc. CUE | BlackRock Inc. BLK | 2,247,978 4.980% | -90,787 (-3.88%) | Filing History |
| 2024-01-31 2:08 pm Purchase | 2023-12-31 | 13G | Cue Biopharma, Inc. CUE | BlackRock Inc. BLK | 2,338,765 5.200% | 1,506,840 (+181.13%) | Filing History |
| 2023-02-14 09:30 am Unchanged | 2022-12-31 | 13G | Cue Biopharma, Inc. CUE | Slate Path Capital LP | 2,402,455 5.600% | 0 (Unchanged) | Filing History |
| 2023-02-03 11:36 am Sale | 2022-12-31 | 13G | Cue Biopharma, Inc. CUE | STATE STREET CORP STT | 141,153 0.330% | -1,521,099 (-91.51%) | Filing History |
| 2022-12-02 5:21 pm Sale | 2022-12-01 | 13G | Cue Biopharma, Inc. CUE | Nantahala Capital Management, LLC | 93,297 0.300% | -2,446,403 (-96.33%) | Filing History |
| 2022-11-18 4:04 pm Purchase | 2022-11-16 | 13G | Cue Biopharma, Inc. CUE | Slate Path Capital LP | 2,402,455 5.600% | 2,402,455 (New Position) | Filing History |
| 2022-07-08 4:57 pm Sale | 2022-06-30 | 13G | Cue Biopharma, Inc. CUE | BlackRock Inc. BLK | 831,925 2.400% | -1,458,344 (-63.68%) | Filing History |
| 2022-02-14 4:23 pm Sale | 2021-12-31 | 13G | Cue Biopharma, Inc. CUE | Corriente Advisors LLC | 0 0.000% | -1,915,219 (Position Closed) | Filing History |
| 2022-02-14 08:09 am Purchase | 2021-12-31 | 13G | Cue Biopharma, Inc. CUE | Nantahala Capital Management, LLC | 2,539,700 8.000% | 32,928 (+1.31%) | Filing History |
| 2022-02-10 1:52 pm Purchase | 2021-12-31 | 13G | Cue Biopharma, Inc. CUE | STATE STREET CORP STT | 1,662,252 5.230% | 1,662,252 (New Position) | Filing History |
| 2022-02-03 4:41 pm Purchase | 2021-12-31 | 13G | Cue Biopharma, Inc. CUE | BlackRock Inc. BLK | 2,290,269 7.200% | 127,291 (+5.88%) | Filing History |
| 2021-02-16 06:28 am Purchase | 2020-12-31 | 13G | Cue Biopharma, Inc. CUE | Corriente Advisors LLC | 1,915,219 6.330% | 1,915,219 (New Position) | Filing History |
| 2021-02-12 3:19 pm Purchase | 2020-12-31 | 13G | Cue Biopharma, Inc. CUE | Nantahala Capital Management, LLC | 2,506,772 8.300% | 1,101,831 (+78.43%) | Filing History |
| 2021-02-12 08:13 am Sale | 2020-12-31 | 13G | Cue Biopharma, Inc. CUE | AVORO CAPITAL ADVISORS LLC | 452,500 1.500% | -1,417,500 (-75.80%) | Filing History |
| 2021-01-29 09:56 am Purchase | 2020-12-31 | 13G | Cue Biopharma, Inc. CUE | BlackRock Inc. BLK | 2,162,978 7.100% | 775,309 (+55.87%) | Filing History |
| 2020-04-21 3:16 pm Sale | 2020-04-21 | 13D | Cue Biopharma, Inc. CUE | MARLETT CHRISTOPHER A | 1,357,821 4.870% | -98,602 (-6.77%) | Filing History |
| 2020-02-14 12:19 pm Purchase | 2019-12-31 | 13G | Cue Biopharma, Inc. CUE | Nantahala Capital Management, LLC | 1,404,941 6.100% | 1,404,941 (New Position) | Filing History |
| 2020-02-14 10:24 am Purchase | 2019-12-31 | 13G | Cue Biopharma, Inc. CUE | AVORO CAPITAL ADVISORS LLC | 1,870,000 8.100% | 1,870,000 (New Position) | Filing History |